During World War II, America discovered that it could retool its thriving automobile industry to churn out tanks and bombers. Check out Nextopics 1st podcast episode, COVID-19: A Microcosm of American Healthcare with Peter Kolchinsky. Peter Kolchinsky steps past the headlines and simple rhetoric to take on directly the most challenging questions we face as a society in balancing the trade-offs between incentivizing and enabling the discovery of breakthrough medicines, and the responsibility we have in ensuring this is done in a sustainable way. What the Wuhan crisis shows, though, is that we are all patients with a common symptom—fear, which many are suffering from now over the prospect of a deadly virus, Covid-19, terrorizing communities and families. Peter Kolchinsky, Ph.D. is a founder, Managing Director, and Portfolio Manager at RA Capital Management, a crossover fund manager dedicated to evidence-based investing in healthcare and life science companies. the insurance value of medical innovation. Peter Kolchinsky. Thank you for your continued support. Peter Kolchinsky, a biotechnology investor and scientist, is Managing Partner of RA Capital Management, L.P., and author of The Great American Drug Deal. Dr. Kolchinsky is a founding Partner and Portfolio Manager at RA Capital. Drugs go generic and become inexpensive over time; hospitals and surgery never do. He received a PhD in Virology from Harvard University. Hear out virologist Peter Kolchinsky's response to Shiv Aroor. He authored the e-book “The Entrepreneur’s Guide to a Biotech Startup.” He also serves on the board of the American Fertility Association and is a board member of several private healthcare companies. Similarly, paying for the medicines our biotechnology industry creates for the diseases that we already know of keeps America prepared for novel health-care threats. He received a Bachelor’s degree from Cornell University. # eConclave | How far are we from the # coronavirus vaccine? A quarterly magazine of urban affairs, published by the Manhattan Institute, edited by Brian C. Anderson. Peter is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools and serves as a Board Member for various publicly- and privately-held companies. Featuring Peter Kolchinsky, PhD '01, founder, Portfolio Manager, and Managing Director at RA Capital Management, ... Peter holds a BS from Cornell University and a PhD in Virology from Harvard University. We are better prepared to respond to such a threat today than ever before. The primary way that we pay for our vaccine and antiviral infrastructure is through health-care taxes (e.g., Medicare and Medicaid), insurance premiums, and patients’ out-of-pocket spending. They may declare that an antiviral medicine is overpriced, based on the value of treating patients with HIV, but no health economist would have foreseen that an HIV drug is now being tested as a possible treatment for the coronavirus. Peter Kolchinsky started RA Capital Management after completing his Ph.D. in virology from Harvard in 2001. Some health economists, such as those at the Institute for Clinical and Economic Review (ICER), believe that they can tell us the right price to pay for each new medicine that the FDA approves. More detailed message would go here to provide context for the user and how to proceed. You can connect with Peter on LinkedIn. Congress needs at least to lower and cap out-of-pocket costs and maybe even consider banning “cost-sharing”—a euphemism, at best—just as it banned insurance plans from refusing to cover preexisting conditions. We can only hope that Congress responds to such reason. Health economists analyze the value of each drug too narrowly. I offered to draft an executive summary and help secure financing. Whether reading the book on your own, as part of a book club, or in a class, we hope this study guide helps stimulate discussion that allows readers to more deeply examine their own attitudes towards healthcare, innovation, and affordability. We look forward to providing you with even more cutting-edge market research, as Topio Networks. Most recently he bought 4,000,000 units of WVE stock worth $80,000,000 on 23 June 2020.. audio Prospects for a Coronavirus Vaccine Peter Kolchinsky, Brian C. Anderson 10 Blocks podcast. That’s a bargain that Congress risks throwing out the window with price controls rooted in myopic math. Considering how important it is to pay for the novel medicines that keep our biotechnology sector up and running, it’s wrong to ask the vulnerable, sick, and poor among us to pay for the infrastructure that brings all of us peace of mind. Virologist Peter Kolchinsky decodes mysteries of #coronavirus Watch him on #eConclave in conversation with Shiv Aroor Full Session: https://bit.ly/34QxgRj The New York governor’s long-running media celebration was largely based on a fiction—his dramatic understatement of Covid-19 deaths in nursing homes. eye on the news Ending Covid Peter Kolchinsky It will take some time, but rest assured: a coronavirus vaccine is coming, and it will work.